Presentation Information
[P1-01]Generation of a site-specific transcription factor blocker as a versatile TF inhibitor
*Hideo Negishi1,2,3,4, Tatsuma Ban5, Mina Kurosawa1, Shonrod Airisshu1, Yusuke Wada1, Tomoya Hayashi1,2,4, Kaiwen Liu1,2,4, Yoshitaka Shirasaki6, Temizoz Burcu1,2,4, Kouji Kobiyama1,2,4, Noriko Toyama-Sorimachi2, Cevayir Coban2,4,7, Tomohiko Tamura5, Tomio Iwasaki8, Ken J Ishii1,2,4,9,10 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 2. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 3. Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan. (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan. (Japan), 5. Department of Immunology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan. (Japan), 6. Division of Photonic Imaging, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. (Japan), 7. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 8. Research and Development Group, Hitachi, Ltd., Ibaraki, Japan. (Japan), 9. Laboratory of Vaccine Science, Immunology Frontier Research Center (IFReC), Osaka University, Osaka, Japan. (Japan), 10. Laboratory of Mockup Vaccine, Center for Vaccine and Adjuvant Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan. (Japan))

Keywords:
transcription,site-specific blocker of TF (siTF),IRF,type I IFN,pyrrole-imidazole polyamide (PIPA)
Password required to view
Log in
or
Comment
To browse or post comments, you must log in.Log in
